Combined Therapeutics (CTx) is a privately held biotechnology company developing the next generation of high-value mRNA vaccines to protect everyone, including vulnerable populations, from global infectious diseases as well as to treat cancer.
The company’s unique and proprietary mRNA platform, with an increased safety profile due to controlled biodistribution and high specificity, is built around Multi Organ Protective (MOPCTx) binding miRNA sequences combined with therapeutic mRNAs, allowing the targeting of therapeutic protein expression in specific tissues while reducing off-target effects to protect key vital organs such as the heart, liver, and kidneys.
The company’s initial focus is on developing vaccines and vaccine adjuvants for infectious diseases and oncology indications, with plans to initiate clinical development in 2024.
OUR TECHNOLOGY
Combined Therapeutics’ platform, MOPCTx, is comprised of a modified mRNA encapsulated in a lipid nanoparticle. The UTR region of the mRNA is modified to contain miRNA binding sequences. Due to the differential expression of miRNA in different cells and tissues in the body, our platform can be targeted to express the antigen preferentially at the site of injection while protecting key vital organs such as the heart, liver, and kidneys.
LATEST NEWS
October 25, 2023
Combined Therapeutics to Present at 11th International mRNA Health Conference
BOSTON, Oct. 25, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the 11th…
October 11, 2023
Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023
BOSTON, Oct. 11, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA vaccines and therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the…